Supplementary Figure S4 from A Phase I Study of Acapatamab, a Half-life Extended, PSMA-Targeting Bispecific T-cell Engager for Metastatic Castration-Resistant Prostate Cancer
Key points are not available for this paper at this time.
Abstract
Acapatamab-induced PSA response in patients who received prior lutetium-PSMA therapy
AIに質問
Like
Bookmark
Share
View Full Paper
AIに質問
Like
Bookmark
Share
View Full Paper
Supplementary Figure S4 from A Phase I Study of Acapatamab, a Half-life Extended, PSMA-Targeting Bispecific T-cell Engager for Metastatic Castration-Resistant Prostate Cancer | Synapse